Seven Fleet Capital Management LP Invests $7.06 Billion in Axsome Therapeutics, Inc. $AXSM

Seven Fleet Capital Management LP bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 28,826 shares of the company’s stock, valued at approximately $7,055,740,000. Axsome Therapeutics comprises about 1.2% of Seven Fleet Capital Management LP’s holdings, making the stock its 20th largest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Pictet Asset Management Holding SA boosted its position in Axsome Therapeutics by 20.4% during the fourth quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock worth $79,643,000 after purchasing an additional 73,925 shares during the period. Norges Bank bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $90,490,000. Axiom Investors LLC DE boosted its holdings in Axsome Therapeutics by 28.7% in the fourth quarter. Axiom Investors LLC DE now owns 63,390 shares of the company’s stock valued at $11,578,000 after acquiring an additional 14,137 shares in the last quarter. Legato Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 90.6% during the 4th quarter. Legato Capital Management LLC now owns 9,627 shares of the company’s stock valued at $1,758,000 after buying an additional 4,576 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Axsome Therapeutics by 60.1% in the fourth quarter. BNP Paribas Financial Markets now owns 304,388 shares of the company’s stock worth $55,593,000 after acquiring an additional 114,282 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on AXSM shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Truist Financial upgraded Axsome Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. Wells Fargo & Company lifted their target price on Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Royal Bank Of Canada lowered their price objective on shares of Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Finally, Morgan Stanley lifted their target price on Axsome Therapeutics from $242.00 to $251.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $267.60.

Insider Activity at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 4,660 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This represents a 39.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roger Jeffs sold 286 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total value of $70,407.48. Following the completion of the sale, the director owned 58,653 shares of the company’s stock, valued at approximately $14,439,195.54. The trade was a 0.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 200,766 shares of company stock worth $46,685,646 over the last 90 days. Corporate insiders own 20.60% of the company’s stock.

Axsome Therapeutics Stock Performance

AXSM opened at $207.15 on Thursday. The company has a market cap of $10.85 billion, a P/E ratio of -55.24 and a beta of 0.65. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. The firm’s 50-day moving average price is $229.34 and its 200-day moving average price is $206.61. Axsome Therapeutics, Inc. has a 52-week low of $112.90 and a 52-week high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The company had revenue of $218.38 million during the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. As a group, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Key Stories Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
• Neutral Sentiment: The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
• Neutral Sentiment: A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
• Negative Sentiment: The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.